Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025, and September 26, 2025, of the upcoming lead plaintiff deadline on March 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SDM securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Smart Digital made false and misleading statements and failed to disclose critical information regarding market manipulation and fraudulent promotion schemes [5]. - Specific allegations include the use of offshore accounts for share dumping, omission of risks related to fraudulent trading, and misleading positive statements about the company's business and prospects [5].

New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Beyond Meat, Inc. (NASDAQ: BYND) between February 27, 2025 and November 11, 2025, both dates inclusive (the "Class Period"), of the important March 24, 2026 lead plaintiff deadline.SO WHAT: If you purchased Beyond Meat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers Class A common stock of Snowflake Inc. (NYSE: SNOW) between June 27, 2023 and the close of the market on February 28, 2024 (4:00 p.m. ET), inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2026. SO WHAT: If you purchased Snowflake Class ...

New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public.SO WHAT: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2026 [3]. - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth emerged [6].

New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of KDDI Corporation (OTC Pink: KDDIY) resulting from allegations that KDDI may have issued materially misleading business information to the investing public.SO WHAT: If you purchased KDDI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].

New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important March 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...